mitoxantrone has been researched along with Vomiting in 29 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Vomiting: The forcible expulsion of the contents of the STOMACH through the MOUTH.
Excerpt | Relevance | Reference |
---|---|---|
"A double-blind clinical trial of mitoxantrone versus methylprednisolone was performed in 49 patients with relapsing, secondary multiple sclerosis." | 9.09 | A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. ( Beguin, C; Carton, H; D'Hooghe, MB; Dooms, G; Lissoir, F; Sindic, CJ; van de Wyngaert, FA, 2001) |
"We investigated the antiemetic effect, safety and usefulness of granisetron tablet on nausea/vomiting induced by cytosine arabinoside (Ara-C) in the chemotherapy for tumors in the hematopoietic organs." | 9.07 | [Study on the inhibitory effect of oral granisetron against nausea/vomiting induced by cytosine arabinoside containing chemotherapy for tumors in the hematopoietic organs]. ( Gondo, H; Harada, M; Matsuishi, H; Omori, F; Otsuka, T; Shibuya, T; Taniguchi, S; Teshima, T; Yamano, Y; Yamazaki, K, 1993) |
"As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF)." | 9.05 | A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Bennett, JM; Byrne, P; DeConti, R; Desai, A; Doroshow, J; Krementz, E; Muggia, F; Plotkin, D; Vogel, C; White, C, 1985) |
"A total of 60 patients with advanced breast cancer were treated with a combination of prednimustine (P: 110 mg/m2, days 1-5), mitoxantrone (M: 12 mg/m2, day 1) and 5-fluorouracil (F: 500 mg/m2, day 1) (PMF)." | 7.68 | Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer. ( Dusleag, J; Kasparek, AK; Lechner, P; Pfeiffer, K; Samonigg, H; Schmid, M; Smola, M; Steindorfer, P; Stöger, H, 1991) |
"In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose." | 7.67 | Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer. ( Armand, JP; Cappelaere, P; Delgado, M; Grimbert, J; Keiling, R; Mathe, G; Metz, R; Misset, JL; Prevot, G, 1985) |
"The therapeutic effects of 4'-Epi-Adriamycin (Epi-ADR), THP-Adriamycin (THP-ADR) and Mitoxantrone on 30 patients with advanced and recurrent breast cancer were analyzed." | 7.67 | [Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer]. ( Hayashi, K; Kitamura, M; Kosaki, G; Takahashi, I; Tominaga, T, 1984) |
"Mitoxantrone was evaluated in a multi-institution trial to define the effective dose for treating acute leukemia, to evaluate its toxicity, and to assess the induction rates for the different types of acute leukemia." | 7.67 | Phase I-II trial of mitoxantrone in acute leukemia. ( Arlin, ZA; Armentrout, S; Cassileth, P; Coleman, M; Daghestani, A; Dukart, G; Gams, R; Schoch, I; Silver, R, 1985) |
"Twenty-three patients with advanced breast cancer were treated with the combination of mitoxantrone and doxorubicin." | 7.67 | Combined mitoxantrone plus doxorubicin in the treatment of breast cancer. ( Lefebvre, BM; Maroun, JA; Perrault, DJ; Stewart, DJ, 1987) |
"Thirty patients with advanced breast cancer, not pretreated with chemotherapy, received a polychemotherapy regimen containing mitoxantrone, fluorouracil and cyclophosphamide at the dose of 10 mg/m2, 500 mg/m2 and 500 mg/m2 i." | 7.67 | Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer. ( Canova, N; Ercolino, L; Martoni, A; Pannuti, F; Rani, P, 1988) |
"Forty-two women with measurable or evaluable advanced breast cancer who had received neither prior chemotherapy for advanced disease nor any anthracycline-containing regimen as adjuvant were entered in a phase II study of mitoxantrone (Novantrone; dihydroxyanthracenedione)." | 7.67 | Mitoxantrone as a first-line treatment of advanced breast cancer. ( Andersson, T; Borgstrom, S; Landys, K; Noppa, H, 1985) |
"Congestive heart failure has been observed in one patient (doxorubicin)." | 6.66 | A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). ( Constanzi, JJ; Cowan, JD; Neidhart, JA; Osborne, CK; Vaughn, CB; Von Hoff, DD, 1985) |
"Mitoxantrone was subsequently given in a five-day schedule at a dose of 10mg/m2 daily to twenty-one patients with relapsed or refractory acute leukaemia or chronic myeloid leukaemia in blast crisis (CML-BC)." | 6.66 | Sequential studies on the role of mitoxantrone in the treatment of acute leukemia. ( Prentice, HG; Robbins, G; Wimperis, JZ, 1985) |
"Mitoxantrone was well tolerated with myelosuppression as the dose-limiting toxicity." | 5.27 | Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study. ( Coleman, R; Cornbleet, M; McDonald, M; Mouridsen, HT; Rainer, H; Rubens, R; Smith, I; Smyth, J; Stuart-Harris, R; van Oosterom, A, 1985) |
"Mitoxantrone is a synthetic aminoanthraquinone we have previously reported to be effective for patients with acute leukemia in relapse." | 5.27 | Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia. ( Cuttner, J; Dutcher, JP; Holland, JF; Paciucci, PA; Strauman, JJ; Wiernik, PH, 1987) |
"A double-blind clinical trial of mitoxantrone versus methylprednisolone was performed in 49 patients with relapsing, secondary multiple sclerosis." | 5.09 | A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. ( Beguin, C; Carton, H; D'Hooghe, MB; Dooms, G; Lissoir, F; Sindic, CJ; van de Wyngaert, FA, 2001) |
"We investigated the antiemetic effect, safety and usefulness of granisetron tablet on nausea/vomiting induced by cytosine arabinoside (Ara-C) in the chemotherapy for tumors in the hematopoietic organs." | 5.07 | [Study on the inhibitory effect of oral granisetron against nausea/vomiting induced by cytosine arabinoside containing chemotherapy for tumors in the hematopoietic organs]. ( Gondo, H; Harada, M; Matsuishi, H; Omori, F; Otsuka, T; Shibuya, T; Taniguchi, S; Teshima, T; Yamano, Y; Yamazaki, K, 1993) |
"As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF)." | 5.05 | A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Bennett, JM; Byrne, P; DeConti, R; Desai, A; Doroshow, J; Krementz, E; Muggia, F; Plotkin, D; Vogel, C; White, C, 1985) |
" Prior to overt cerebral invasion by NHL, she had a thiamine deficiency with very low thiamine concentrations in the CSF, probably caused by protracted vomiting and increased vitamin B1 consumption by intrathecal tumor cells." | 3.70 | Downbeat nystagmus caused by thiamine deficiency: an unusual presentation of CNS localization of large cell anaplastic CD 30-positive non-Hodgkin's lymphoma. ( Boerman, RH; Mattijssen, V; Mulder, AH; Raemaekers, JM, 1999) |
"A total of 60 patients with advanced breast cancer were treated with a combination of prednimustine (P: 110 mg/m2, days 1-5), mitoxantrone (M: 12 mg/m2, day 1) and 5-fluorouracil (F: 500 mg/m2, day 1) (PMF)." | 3.68 | Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer. ( Dusleag, J; Kasparek, AK; Lechner, P; Pfeiffer, K; Samonigg, H; Schmid, M; Smola, M; Steindorfer, P; Stöger, H, 1991) |
"Thirty patients with advanced breast cancer, not pretreated with chemotherapy, received a polychemotherapy regimen containing mitoxantrone, fluorouracil and cyclophosphamide at the dose of 10 mg/m2, 500 mg/m2 and 500 mg/m2 i." | 3.67 | Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer. ( Canova, N; Ercolino, L; Martoni, A; Pannuti, F; Rani, P, 1988) |
"Mitoxantrone was evaluated in a multi-institution trial to define the effective dose for treating acute leukemia, to evaluate its toxicity, and to assess the induction rates for the different types of acute leukemia." | 3.67 | Phase I-II trial of mitoxantrone in acute leukemia. ( Arlin, ZA; Armentrout, S; Cassileth, P; Coleman, M; Daghestani, A; Dukart, G; Gams, R; Schoch, I; Silver, R, 1985) |
"Forty-two women with measurable or evaluable advanced breast cancer who had received neither prior chemotherapy for advanced disease nor any anthracycline-containing regimen as adjuvant were entered in a phase II study of mitoxantrone (Novantrone; dihydroxyanthracenedione)." | 3.67 | Mitoxantrone as a first-line treatment of advanced breast cancer. ( Andersson, T; Borgstrom, S; Landys, K; Noppa, H, 1985) |
"Twenty-three patients with advanced breast cancer were treated with the combination of mitoxantrone and doxorubicin." | 3.67 | Combined mitoxantrone plus doxorubicin in the treatment of breast cancer. ( Lefebvre, BM; Maroun, JA; Perrault, DJ; Stewart, DJ, 1987) |
"In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose." | 3.67 | Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer. ( Armand, JP; Cappelaere, P; Delgado, M; Grimbert, J; Keiling, R; Mathe, G; Metz, R; Misset, JL; Prevot, G, 1985) |
"The therapeutic effects of 4'-Epi-Adriamycin (Epi-ADR), THP-Adriamycin (THP-ADR) and Mitoxantrone on 30 patients with advanced and recurrent breast cancer were analyzed." | 3.67 | [Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer]. ( Hayashi, K; Kitamura, M; Kosaki, G; Takahashi, I; Tominaga, T, 1984) |
"Infections were the cause of death in nine patients, including four in the CMC5 group and five in the CMC3 group." | 2.70 | Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. ( Boguradzki, P; Błoński, JZ; Calbecka, M; Ceglarek, B; Dmoszyńska, A; Dwilewicz-Trojaczek, J; Góra-Tybor, I; Kasznicki, M; Konopka, L; Kuliczkowski, K; Moskwa-Sroka, B; Nowak, W; Robak, T; Skotnicki, AB; Stella-Hołowiecka, B; Sułek, J; Wołowiec, D, 2001) |
" Ten dogs were given mitoxantrone at a dosage of 5." | 2.67 | Toxicoses associated with the administration of mitoxantrone to dogs with malignant tumors: a dose escalation study. ( Atwater, SW; Bergman, PJ; Chen, C; Ciekot, PA; Moore, AS; Ogilvie, GK; Walters, LM, 1994) |
"Mitoxantrone has demonstrable clinical activity when administered intravenously in a wide range of malignancies." | 2.67 | Phase I/II study of intraperitoneal mitoxantrone in refractory ovarian cancer. ( Aartsen, E; Dubbelman, R; Mandjes, I; McVie, JG; Oza, AM; Soepenberg, O; ten Bokkel Huinink, W, 1994) |
"Thirty children with refractory acute lymphocytic leukemia (ALL) were treated with mitoxantrone, 8 mg/m2/day, for 5 days." | 2.67 | Phase II trial of mitoxantrone in acute lymphocytic leukemia of childhood. A Pediatric Oncology Group study. ( Estrada, J; Graham, ML; Ragab, AH; Rosen, D; Starling, KA; Wilkenson, RW; Wilkerson, RW, 1991) |
" every 3 weeks in escalating doses combined with a fixed dose of s." | 2.67 | Phase I study of escalating dose mitoxantrone in combination with alpha-2-interferon in patients with advanced solid tumors. ( Dal Fior, S; Favretto, S; Gasparini, G; Panizzoni, GA; Pozza, F; Von Hoff, DD, 1991) |
"Mitoxantrone (Novantrone), is an anthracenedione which in preclinical studies demonstrated a spectrum of antitumor activity similar to the anthracyclines, but with less cardiotoxicity." | 2.66 | Mitoxantrone: an overview of safety and toxicity. ( Bernstein, T; Cartwright, K; Dukart, G; Goldberg, J; Posner, LE, 1985) |
"Congestive heart failure has been observed in one patient (doxorubicin)." | 2.66 | A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). ( Constanzi, JJ; Cowan, JD; Neidhart, JA; Osborne, CK; Vaughn, CB; Von Hoff, DD, 1985) |
"Mitoxantrone was subsequently given in a five-day schedule at a dose of 10mg/m2 daily to twenty-one patients with relapsed or refractory acute leukaemia or chronic myeloid leukaemia in blast crisis (CML-BC)." | 2.66 | Sequential studies on the role of mitoxantrone in the treatment of acute leukemia. ( Prentice, HG; Robbins, G; Wimperis, JZ, 1985) |
" Although the primary purpose of this study was to determine a clinically useful dosage and to characterize the toxicoses associated with mitoxantrone administration, each cat was monitored for response to treatment." | 1.29 | Toxicoses and efficacy associated with administration of mitoxantrone to cats with malignant tumors. ( Atwater, SW; Ciekot, PE; Elmslie, RE; Klein, MK; Moore, AS; Obradovich, JE; Ogilvie, GK; Salmon, MD; Straw, RC; Vail, DM, 1993) |
"To determine optimal dosage, Dihydroxyanthracenedione (DHAD) was given once daily for 3 days at dosage levels of 6, 7, 8, and 10 mg/m2 in combination with a 7-day continuous infusion of cytosine arabinoside (Ara-C)." | 1.27 | Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C). ( Civin, CI; Krischer, J; Land, VJ; Ragab, AH; Steuber, CP; Vietti, TJ, 1987) |
"Mitoxantrone is a synthetic aminoanthraquinone we have previously reported to be effective for patients with acute leukemia in relapse." | 1.27 | Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia. ( Cuttner, J; Dutcher, JP; Holland, JF; Paciucci, PA; Strauman, JJ; Wiernik, PH, 1987) |
"Mitoxantrone was well tolerated with myelosuppression as the dose-limiting toxicity." | 1.27 | Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study. ( Coleman, R; Cornbleet, M; McDonald, M; Mouridsen, HT; Rainer, H; Rubens, R; Smith, I; Smyth, J; Stuart-Harris, R; van Oosterom, A, 1985) |
"Ametantrone was extensively distributed (apparent volume of distribution, 26." | 1.27 | A phase I trial of ametantrone acetate (NSC-287513). ( Bender, JF; Gams, RA; Grillo-López, AJ; Ostroy, F, 1985) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 15 (51.72) | 18.7374 |
1990's | 11 (37.93) | 18.2507 |
2000's | 3 (10.34) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Tominaga, T | 1 |
Kitamura, M | 1 |
Hayashi, K | 1 |
Takahashi, I | 1 |
Kosaki, G | 1 |
Sonneveld, P | 1 |
de Ridder, M | 1 |
van der Lelie, H | 1 |
Nieuwenhuis, K | 1 |
Schouten, H | 1 |
Mulder, A | 1 |
van Reijswoud, I | 1 |
Hop, W | 1 |
Lowenberg, B | 1 |
Ogilvie, GK | 3 |
Moore, AS | 3 |
Chen, C | 1 |
Ciekot, PA | 1 |
Atwater, SW | 2 |
Bergman, PJ | 1 |
Walters, LM | 1 |
Oza, AM | 1 |
ten Bokkel Huinink, W | 1 |
Dubbelman, R | 1 |
Soepenberg, O | 1 |
Mandjes, I | 1 |
Aartsen, E | 1 |
McVie, JG | 1 |
Obradovich, JE | 2 |
Elmslie, RE | 2 |
Vail, DM | 2 |
Straw, RC | 2 |
Salmon, MD | 1 |
Klein, MK | 1 |
Ciekot, PE | 1 |
Matsuishi, H | 1 |
Harada, M | 1 |
Gondo, H | 1 |
Otsuka, T | 1 |
Teshima, T | 1 |
Yamano, Y | 1 |
Omori, F | 1 |
Shibuya, T | 1 |
Yamazaki, K | 1 |
Taniguchi, S | 1 |
Mulder, AH | 1 |
Raemaekers, JM | 1 |
Boerman, RH | 1 |
Mattijssen, V | 1 |
Thurnher, D | 1 |
Kornfehl, J | 1 |
Burian, M | 1 |
Gedlicka, C | 1 |
Selzer, E | 1 |
Quint, C | 1 |
Neuchrist, C | 1 |
Kornek, GV | 1 |
Robak, T | 1 |
Błoński, JZ | 1 |
Kasznicki, M | 1 |
Góra-Tybor, I | 1 |
Dwilewicz-Trojaczek, J | 1 |
Boguradzki, P | 1 |
Konopka, L | 1 |
Ceglarek, B | 1 |
Sułek, J | 1 |
Kuliczkowski, K | 1 |
Wołowiec, D | 1 |
Stella-Hołowiecka, B | 1 |
Skotnicki, AB | 1 |
Nowak, W | 1 |
Moskwa-Sroka, B | 1 |
Dmoszyńska, A | 1 |
Calbecka, M | 1 |
van de Wyngaert, FA | 1 |
Beguin, C | 1 |
D'Hooghe, MB | 1 |
Dooms, G | 1 |
Lissoir, F | 1 |
Carton, H | 1 |
Sindic, CJ | 1 |
Gasparini, G | 1 |
Dal Fior, S | 1 |
Pozza, F | 1 |
Panizzoni, GA | 1 |
Favretto, S | 1 |
Von Hoff, DD | 2 |
Graham, ML | 1 |
Estrada, J | 1 |
Ragab, AH | 2 |
Starling, KA | 1 |
Rosen, D | 1 |
Wilkenson, RW | 1 |
Wilkerson, RW | 1 |
Samonigg, H | 1 |
Stöger, H | 1 |
Kasparek, AK | 1 |
Schmid, M | 1 |
Dusleag, J | 1 |
Pfeiffer, K | 1 |
Smola, M | 1 |
Steindorfer, P | 1 |
Lechner, P | 1 |
Curtis, CR | 1 |
Dickinson, K | 1 |
Cooper, MF | 1 |
Withrow, SJ | 1 |
Hiddemann, W | 1 |
Büchner, T | 1 |
Heil, G | 1 |
Schumacher, K | 1 |
Diedrich, H | 1 |
Maschmeyer, G | 1 |
Ho, AD | 1 |
Planker, M | 1 |
Gerith-Stolzenburg, S | 1 |
Donhuijsen-Ant, R | 1 |
Martoni, A | 2 |
Rani, P | 1 |
Ercolino, L | 1 |
Canova, N | 1 |
Pannuti, F | 2 |
Paciucci, PA | 1 |
Dutcher, JP | 1 |
Cuttner, J | 1 |
Strauman, JJ | 1 |
Wiernik, PH | 1 |
Holland, JF | 1 |
Steuber, CP | 1 |
Land, VJ | 1 |
Civin, CI | 1 |
Krischer, J | 1 |
Vietti, TJ | 1 |
Stewart, DJ | 1 |
Perrault, DJ | 1 |
Maroun, JA | 1 |
Lefebvre, BM | 1 |
Arlin, ZA | 1 |
Silver, R | 1 |
Cassileth, P | 1 |
Armentrout, S | 1 |
Gams, R | 1 |
Daghestani, A | 1 |
Coleman, M | 1 |
Schoch, I | 1 |
Dukart, G | 2 |
Posner, LE | 1 |
Goldberg, J | 1 |
Bernstein, T | 1 |
Cartwright, K | 1 |
Cowan, JD | 1 |
Osborne, CK | 1 |
Neidhart, JA | 1 |
Constanzi, JJ | 1 |
Vaughn, CB | 1 |
Bennett, JM | 1 |
Byrne, P | 1 |
Desai, A | 1 |
White, C | 1 |
DeConti, R | 1 |
Vogel, C | 1 |
Krementz, E | 1 |
Muggia, F | 1 |
Doroshow, J | 1 |
Plotkin, D | 1 |
Prentice, HG | 1 |
Wimperis, JZ | 1 |
Robbins, G | 1 |
Landys, K | 1 |
Borgstrom, S | 1 |
Andersson, T | 1 |
Noppa, H | 1 |
Mouridsen, HT | 1 |
Cornbleet, M | 1 |
Stuart-Harris, R | 1 |
Smith, I | 1 |
Coleman, R | 1 |
Rubens, R | 1 |
McDonald, M | 1 |
Rainer, H | 1 |
van Oosterom, A | 1 |
Smyth, J | 1 |
Metz, R | 1 |
Delgado, M | 1 |
Keiling, R | 1 |
Cappelaere, P | 1 |
Armand, JP | 1 |
Prevot, G | 1 |
Misset, JL | 1 |
Grimbert, J | 1 |
Mathe, G | 1 |
Periti, P | 1 |
della Cuna, GR | 1 |
Mazzei, T | 1 |
Preti, P | 1 |
Mini, E | 1 |
Gams, RA | 1 |
Ostroy, F | 1 |
Bender, JF | 1 |
Grillo-López, AJ | 1 |
13 trials available for mitoxantrone and Vomiting
Article | Year |
---|---|
Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined | 1995 |
Toxicoses associated with the administration of mitoxantrone to dogs with malignant tumors: a dose escalation study.
Topics: Animals; Bone Marrow; Diarrhea; Dog Diseases; Dogs; Female; Follow-Up Studies; Leukocyte Count; Logi | 1994 |
Phase I/II study of intraperitoneal mitoxantrone in refractory ovarian cancer.
Topics: Abdominal Pain; Female; Hematologic Diseases; Humans; Injections, Intraperitoneal; Middle Aged; Mito | 1994 |
[Study on the inhibitory effect of oral granisetron against nausea/vomiting induced by cytosine arabinoside containing chemotherapy for tumors in the hematopoietic organs].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyta | 1993 |
Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Anemia; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2001 |
Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cladribine; Cohort Stud | 2001 |
A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.
Topics: Adult; Alopecia; Contrast Media; Double-Blind Method; Female; Follow-Up Studies; Gadolinium; Humans; | 2001 |
Phase I study of escalating dose mitoxantrone in combination with alpha-2-interferon in patients with advanced solid tumors.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relation | 1991 |
Phase II trial of mitoxantrone in acute lymphocytic leukemia of childhood. A Pediatric Oncology Group study.
Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; Drug Evaluation; Female; Humans; | 1991 |
Mitoxantrone: an overview of safety and toxicity.
Topics: Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Clini | 1985 |
A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study).
Topics: Adult; Aged; Alopecia; Anthracenes; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Clinica | 1985 |
A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Anthraquinones; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; | 1985 |
Sequential studies on the role of mitoxantrone in the treatment of acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Agranulocytosis; Anthraquinones; Antineoplastic Agents; Bone | 1985 |
16 other studies available for mitoxantrone and Vomiting
Article | Year |
---|---|
[Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer].
Topics: Adult; Aged; Alopecia; Anthraquinones; Breast Neoplasms; Doxorubicin; Epirubicin; Female; Humans; Mi | 1984 |
Toxicoses and efficacy associated with administration of mitoxantrone to cats with malignant tumors.
Topics: Animals; Anorexia; Carcinoma, Squamous Cell; Cat Diseases; Cats; Chemotherapy, Adjuvant; Dose-Respon | 1993 |
Downbeat nystagmus caused by thiamine deficiency: an unusual presentation of CNS localization of large cell anaplastic CD 30-positive non-Hodgkin's lymphoma.
Topics: Adult; Anisocoria; Antineoplastic Combined Chemotherapy Protocols; Aphasia; Bleomycin; Brain Neoplas | 1999 |
Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chi-Square Distributi | 1991 |
Toxicoses associated with administration of mitoxantrone to dogs with malignant tumors.
Topics: Animals; Anorexia; Bone Marrow; Diarrhea; Dog Diseases; Dogs; Female; Lymphoma; Male; Mitoxantrone; | 1991 |
Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1990 |
Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosph | 1988 |
Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Diarrhea; Drug Administrati | 1987 |
Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Hea | 1987 |
Combined mitoxantrone plus doxorubicin in the treatment of breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Breast | 1987 |
Phase I-II trial of mitoxantrone in acute leukemia.
Topics: Acute Disease; Adult; Aged; Anthraquinones; Drug Evaluation; Female; Heart; Humans; Leukemia; Leukem | 1985 |
Mitoxantrone as a first-line treatment of advanced breast cancer.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Cardiac Output; Female; Heart; | 1985 |
Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study.
Topics: Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Drug Ev | 1985 |
Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer.
Topics: Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Cycloph | 1985 |
First-line combination chemotherapy with mitoxantrone and cyclophosphamide in advanced breast cancer.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 1985 |
A phase I trial of ametantrone acetate (NSC-287513).
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Bone Marrow; Drug Administration Schedule; Drug | 1985 |